REGiMMUNE Corporation is a biotechnology company that was founded in 2006. The company is focused on developing novel medicines with immune regulating technology and primarily operates in the Biopharma, Biotechnology, and Health Care industries. Their last investment, a significant ¥650.00M Series E investment, took place on 10 May 2017. Noteworthy investors in this round included Mitsubishi UFJ Capital, SMBC Venture Capital, JAIC, Iyogin Capital, Hiroshima Venture Capital, Ogaki Kyoritsu Bank, Oita Venture Capital, and Miyako Capital.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | ¥650.00M | 8 |
|
10 May 2017 |
| Series D | $9.20M | 9 |
|
14 Feb 2014 |
| Series C | $5.00M | 5 |
|
01 Feb 2012 |
| Corporate Round | ¥20.00M | 1 | Medinet Global | 27 Jan 2012 |
| Grant | $12.00M | 1 | Japan Science and Technology Agency | 08 Dec 2008 |
No recent news or press coverage available for REGiMMUNE Corporation.
We care about your data, and we'd love to use cookies make your experience better.
